MX360857B - Régimen de dosificación para inhibidores de janus quinasa (jak). - Google Patents
Régimen de dosificación para inhibidores de janus quinasa (jak).Info
- Publication number
- MX360857B MX360857B MX2015000871A MX2015000871A MX360857B MX 360857 B MX360857 B MX 360857B MX 2015000871 A MX2015000871 A MX 2015000871A MX 2015000871 A MX2015000871 A MX 2015000871A MX 360857 B MX360857 B MX 360857B
- Authority
- MX
- Mexico
- Prior art keywords
- jak
- janus
- mammal
- dosage regime
- quinasa
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 3
- 102000015617 Janus Kinases Human genes 0.000 abstract 2
- 108010024121 Janus Kinases Proteins 0.000 abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 abstract 2
- 206010012434 Dermatitis allergic Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261674289P | 2012-07-20 | 2012-07-20 | |
| US201361815803P | 2013-04-25 | 2013-04-25 | |
| PCT/US2013/051015 WO2014015107A1 (en) | 2012-07-20 | 2013-07-18 | Dosing regimen for janus kinase (jak) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015000871A MX2015000871A (es) | 2015-05-07 |
| MX360857B true MX360857B (es) | 2018-11-20 |
Family
ID=48901189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015000871A MX360857B (es) | 2012-07-20 | 2013-07-18 | Régimen de dosificación para inhibidores de janus quinasa (jak). |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9522151B2 (enExample) |
| EP (1) | EP2874630B1 (enExample) |
| JP (2) | JP6022063B2 (enExample) |
| KR (2) | KR20150028299A (enExample) |
| CN (2) | CN108354938A (enExample) |
| AU (1) | AU2013292547B2 (enExample) |
| BR (1) | BR112015000808A2 (enExample) |
| CA (1) | CA2878867C (enExample) |
| CY (1) | CY1121436T1 (enExample) |
| DK (1) | DK2874630T3 (enExample) |
| ES (1) | ES2707627T3 (enExample) |
| HK (2) | HK1209314A1 (enExample) |
| HR (1) | HRP20182088T1 (enExample) |
| HU (1) | HUE042771T2 (enExample) |
| IN (1) | IN2015DN00370A (enExample) |
| LT (1) | LT2874630T (enExample) |
| MX (1) | MX360857B (enExample) |
| NZ (1) | NZ703152A (enExample) |
| PL (1) | PL2874630T3 (enExample) |
| PT (1) | PT2874630T (enExample) |
| RS (1) | RS58242B1 (enExample) |
| SI (1) | SI2874630T1 (enExample) |
| SM (1) | SMT201900044T1 (enExample) |
| WO (1) | WO2014015107A1 (enExample) |
| ZA (1) | ZA201500134B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2958921T1 (sl) | 2013-02-22 | 2017-12-29 | Pfizer Inc. | Derivati pirolo(2,3-d)pirimidina kot inhibitorji Janus kinaz (JAK) |
| JP6585158B2 (ja) | 2014-08-12 | 2019-10-02 | ファイザー・インク | ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体 |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| SG10201913990RA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10973913B2 (en) | 2016-02-16 | 2021-04-13 | Washington University | JAK inhibitors and uses thereof |
| CN107098908B (zh) * | 2016-02-23 | 2021-01-08 | 欣凯医药科技(上海)有限公司 | 一种吡咯并嘧啶类化合物的制备方法和应用 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| FI3915989T3 (fi) * | 2019-01-30 | 2023-09-20 | Felicamed Biotechnology Co Ltd | Jak:n estäjä ja sen valmistusmenetelmä |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| US11827657B2 (en) | 2020-12-18 | 2023-11-28 | Boehringer Ingelheim Animal Health USA Inc. | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof |
| US20240300943A1 (en) * | 2021-03-16 | 2024-09-12 | Hk Inno.N Corporation | Novel salts of heterocyclic compound as protein kinase inhibitor and uses thereof |
| WO2022222948A1 (zh) * | 2021-04-22 | 2022-10-27 | 深圳微芯生物科技股份有限公司 | 包含jak3/jak1/tbk1选择性抑制剂的药物组合物及其医药用途 |
| WO2024259429A2 (en) * | 2023-06-16 | 2024-12-19 | The University Of Chicago | Methods and compositions for pharmaceutically relevant interactions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69916833T2 (de) * | 1998-06-19 | 2005-04-14 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-verbindungen |
| ES2467109T3 (es) | 2008-08-20 | 2014-06-11 | Zoetis Llc | Compuestos de pirrolo[2,3-d]pirimidina |
-
2013
- 2013-07-18 ES ES13742573T patent/ES2707627T3/es active Active
- 2013-07-18 LT LTEP13742573.2T patent/LT2874630T/lt unknown
- 2013-07-18 CN CN201810369706.3A patent/CN108354938A/zh active Pending
- 2013-07-18 DK DK13742573.2T patent/DK2874630T3/en active
- 2013-07-18 CA CA2878867A patent/CA2878867C/en active Active
- 2013-07-18 WO PCT/US2013/051015 patent/WO2014015107A1/en not_active Ceased
- 2013-07-18 AU AU2013292547A patent/AU2013292547B2/en active Active
- 2013-07-18 CN CN201380038563.3A patent/CN104470525A/zh active Pending
- 2013-07-18 BR BR112015000808A patent/BR112015000808A2/pt not_active Application Discontinuation
- 2013-07-18 IN IN370DEN2015 patent/IN2015DN00370A/en unknown
- 2013-07-18 NZ NZ703152A patent/NZ703152A/en unknown
- 2013-07-18 KR KR1020157001085A patent/KR20150028299A/ko not_active Ceased
- 2013-07-18 US US14/415,047 patent/US9522151B2/en active Active
- 2013-07-18 HU HUE13742573A patent/HUE042771T2/hu unknown
- 2013-07-18 HR HRP20182088TT patent/HRP20182088T1/hr unknown
- 2013-07-18 PL PL13742573T patent/PL2874630T3/pl unknown
- 2013-07-18 HK HK15109423.1A patent/HK1209314A1/xx unknown
- 2013-07-18 JP JP2015523243A patent/JP6022063B2/ja active Active
- 2013-07-18 KR KR1020177007913A patent/KR20170034949A/ko not_active Ceased
- 2013-07-18 EP EP13742573.2A patent/EP2874630B1/en not_active Revoked
- 2013-07-18 RS RS20190051A patent/RS58242B1/sr unknown
- 2013-07-18 MX MX2015000871A patent/MX360857B/es active IP Right Grant
- 2013-07-18 SM SM20190044T patent/SMT201900044T1/it unknown
- 2013-07-18 PT PT13742573T patent/PT2874630T/pt unknown
- 2013-07-18 SI SI201331328T patent/SI2874630T1/sl unknown
-
2015
- 2015-01-08 ZA ZA2015/00134A patent/ZA201500134B/en unknown
-
2016
- 2016-08-05 JP JP2016154135A patent/JP2017019816A/ja active Pending
-
2018
- 2018-08-23 HK HK18110906.2A patent/HK1252083A1/zh unknown
-
2019
- 2019-02-14 CY CY20191100203T patent/CY1121436T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX360857B (es) | Régimen de dosificación para inhibidores de janus quinasa (jak). | |
| BR112020008664A8 (pt) | Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo | |
| BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
| MX2016000271A (es) | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. | |
| MX2016003486A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
| MX2019009853A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| NI201600051A (es) | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores | |
| BR112015020350A2 (pt) | derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| BR112016029853A2 (pt) | compostos de indazol substituído como inibidores de irak4 | |
| MX373964B (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
| BR112014004504A2 (pt) | "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase" | |
| EA201391390A1 (ru) | Циклопропиламины в качестве ингибиторов lsd | |
| BR112017003433A2 (pt) | inibidores espirocíclicos de catepsina c | |
| MX2018014231A (es) | Metodos y composiciones para tratar canceres resistentes al inhibidor de la via de cinasas proteicas activadas por mitogeno (mapk), no cinasas extracelulares de señal regulada (erk). | |
| CR20160308A (es) | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores | |
| MX379286B (es) | INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe). | |
| BR112015003729A2 (pt) | composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente | |
| CR20140036A (es) | Compuesto inhibidor de la señalización de la trayectoria notch | |
| UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| MX2016005446A (es) | Intervenciones a base de angiopoyetina para tratar la malaria cerebral. | |
| CO2017011778A2 (es) | Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |